GSK to part ways with 'most' Bel­lus Health em­ploy­ees a year af­ter $2B buy

Many of the em­ploy­ees be­hind GSK’s late-stage in­ves­ti­ga­tion­al drug for chron­ic cough will be let go at the end of March.

“Af­ter hav­ing com­plet­ed the tran­si­tion ac­tiv­i­ties linked to the GSK ac­qui­si­tion, most Bel­lus Health em­ploy­ees will be wrap­ping up their in­volve­ment with the com­pa­ny on March 31,” Rober­to Belli­ni, the long­time CEO of Bel­lus, wrote Thurs­day on LinkedIn.

A year ago, GSK bought the Cana­di­an biotech for $2 bil­lion for Bel­lus’ Phase 3 chron­ic cough can­di­date, which was ex­pect­ed to com­pete with Mer­ck’s P2X3 an­tag­o­nist. That drug was re­ject­ed by the FDA for a sec­ond time in De­cem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER